Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Marshall Wace

Investor type Hedge Fund
Founders Ian Wace Paul Marshall


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 39
Average round size
The average size of a deal this fund participated in
Portfolio companies 30
Rounds per year 1.50
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 5
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Financial Services
  • FinTech
  • Cryptocurrency

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Marshall Wace:
Typical Co-investors
Marshall Wace is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Marshall Wace:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AMED Ventures California, San Francisco, United States
Capital Angel Network Canada, Ontario, Ottawa
CH Investment Partners Dallas, Texas, United States
Chugai Pharmaceutical Chiyoda, Japan
City of Oulu -
Giant Rich Co., Ltd. England, London, United Kingdom
Grupo Modelo Distrito Federal, Mexico, Mexico City
Happy Capital Aquitaine, Bordeaux, France
Huikedu Group Beijing, Beijing, China
JZ Securities Beijing, Beijing, China
OEL Venture Investments California, San Francisco, United States
Ospraie Management New York, New York, United States
SAME Capital Ltd Cayman Islands, Grand Cayman
The E14 Fund Boston, Massachusetts, United States
Triglav d.d. Ljubljana, Ljubljana Urban Commune, Slovenia
UTI Mutual Fund Bandra, India, Maharashtra
VDOSH California, Encino, United States
Vega Ventures New York, New York, United States
Zing Capital United States, Vancouver, Washington

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Karyopharm Therapeutics

Health Care
$165M05 Dec 2022 Newton, Massachusetts, United States

TRM Labs

$70M09 Nov 2022 Maryland, United States


Health Care
$125M13 Oct 2022 Basel, Basel-City, Switzerland


Health Care
$300M13 Sep 2022 Los Angeles, California, United States


Health Care
Medical Device
$67M12 Sep 2022 Costa Mesa, California, United States

$25M06 Sep 2022 Zurich, Zurich, Switzerland


Alternative Medicine
$40M13 Jun 2022 Boston, Massachusetts, United States


Financial Services
Health Insurance
$120M29 Apr 2022 Mumbai, Maharashtra, India


Financial Services
Personal Finance
$400M12 Apr 2022 Boston, Massachusetts, United States
Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

– Neurogastrx, a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced the successful completion of a $60m Series B crossover round led by Vivo Capital.
– Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors.
– Proceeds from the financing will be used to advance the company’s pipeline of GI therapies for serious conditions that impact millions of people yet are not effectively treated.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Marshall Wace?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: